专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010132827A1 LOW-MOLECULAR DEXTRAN FOR POWDER INHALATIONS 审中-公开
标题翻译：低分子量粉剂用于粉末吸入
公开(公告)号：WO2010132827A1
公开(公告)日：2010-11-18
申请号：PCT/US2010/034992
申请日：2010-05-14
申请人： BEND RESEARCH, INC. , VODAK, David, T. , DOBRY, Daniel, E. , LYON, David, K. , FRIESEN, Dwayne, T.
发明人： VODAK, David, T. , DOBRY, Daniel, E. , LYON, David, K. , FRIESEN, Dwayne, T.
IPC分类号： A61K9/72 , A61K38/28
CPC分类号： A61K9/0075
摘要： Pharmaceutical compositions suitable for inhalation are disclosed. The compositions comprise a dry powder comprising particles having a mean geometric diameter of 0.5 to 100 μm. The particles comprise from 0.01 to 99 wt % of an active and from 1 to 99.99 wt% of a dextran polymer having a molecular weight in the range of 1,000 to 30,000 daltons. The particles may be prepared by dissolving the active and the dextran polymer in a solvent, and spray drying the solution to form the particles.
摘要翻译：公开了适于吸入的药物组合物。组合物包含干粉，其包含平均几何直径为0.5至100μm的颗粒。颗粒包含0.01至99重量％的活性物质和1至99.99重量％的分子量为1,000至30,000道尔顿的葡聚糖聚合物。可以通过将活性物质和葡聚糖聚合物溶解在溶剂中来制备颗粒，并将溶液喷雾干燥以形成颗粒。

2. 发明申请

WO2008047201A3 SOLID DISPERSION COMPRISING A POORLY WATER SOLUBLE DRUG 审中-公开
标题翻译：固体分散体包含不良溶于水的溶液
公开(公告)号：WO2008047201A3
公开(公告)日：2008-06-26
申请号：PCT/IB2007003062
申请日：2007-10-08
申请人： PFIZER PROD INC , KETNER RODNEY JAMES , LORENZ DOUGLAS ALAN , LYON DAVID KEITH
发明人： KETNER RODNEY JAMES , LORENZ DOUGLAS ALAN , LYON DAVID KEITH
IPC分类号： A61K9/16 , A61K31/437 , A61K31/501 , A61K31/522 , C07D213/00 , C07D405/00 , C07D471/00 , C07D473/00 , C07D519/00
CPC分类号： A61K9/1652 , A61K9/1617 , A61K31/437 , A61K31/501 , A61K31/522 , C07D405/12 , C07D471/04 , C07D473/34
摘要： Pharmaceutical compositions comprising a poorly water soluble ionizable drug, a cationic species and a dispersion polymer are disclosed, together with a process for forming the compositions. The neutral form of the drug has (i) a solubility of less than 1 mg/mL in aqueous solution at a pH between 6 and 7, (ii) a solubility of less than 20 mg/mL in a volatile organic solvent, and (iii) an acidic pKa value of greater than 5. At least 90 wt% of the drug in the solid dispersion being in a non-crystalline form. The drug, the cationic species, and the dispersion polymer constitute at least 80 wt% of the solid dispersion.
摘要翻译：公开了包含难溶于水的可离子化药物，阳离子物质和分散体聚合物的药物组合物以及用于形成组合物的方法。中性形式的药物具有（i）在6至7之间的pH下在水溶液中的溶解度小于1mg / mL，（ii）在挥发性有机溶剂中的溶解度小于20mg / mL，和（ iii）大于5的酸性pKa值。固体分散体中至少90wt％的药物是非结晶形式。药物，阳离子物质和分散体聚合物构成固体分散体的至少80重量％。

3. 发明申请

WO2006131806A3 MULTIPARTICULATES COMPRISING LOW-SOLUBILITY DRUGS AND CARRIERS THAT RESULT IN RAPID DRUG RELEASE 审中-公开
公开(公告)号：WO2006131806A3
公开(公告)日：2006-12-14
申请号：PCT/IB2006/001461
申请日：2006-05-26
申请人： PFIZER PRODUCTS INC. , APPEL, Leah, Elizabeth , FRIESEN, Dwayne, Thomas , LYON, David, Keith , MCCRAY, Scott, Baldwin , SHOCKEY, Joshua, Richard
发明人： APPEL, Leah, Elizabeth , FRIESEN, Dwayne, Thomas , LYON, David, Keith , MCCRAY, Scott, Baldwin , SHOCKEY, Joshua, Richard
IPC分类号： A61K9/16
摘要： Multiparticulates of low-solubility drugs and carriers that result in rapid release of the drug are disclosed.

4. 发明申请

WO2006131806A2 MULTIPARTICULATES COMPRISING LOW-SOLUBILITY DRUGS AND CARRIERS THAT RESULT IN RAPID DRUG RELEASE 审中-公开
标题翻译：包含低溶解性药物和携带者的多重试验结果发生在快速释放药物
公开(公告)号：WO2006131806A2
公开(公告)日：2006-12-14
申请号：PCT/IB2006001461
申请日：2006-05-26
申请人： PFIZER PROD INC , APPEL LEAH ELIZABETH , FRIESEN DWAYNE THOMAS , LYON DAVID KEITH , MCCRAY SCOTT BALDWIN , SHOCKEY JOSHUA RICHARD
发明人： APPEL LEAH ELIZABETH , FRIESEN DWAYNE THOMAS , LYON DAVID KEITH , MCCRAY SCOTT BALDWIN , SHOCKEY JOSHUA RICHARD
IPC分类号： A61K9/16
CPC分类号： A61K9/1617 , A61K9/1623 , A61K9/1694
摘要： Multiparticulates of low-solubility drugs and carriers that result in rapid release of the drug are disclosed.
摘要翻译：公开了导致药物快速释放的低溶解度药物和载体的多微粒。

5. 发明申请

WO2005053650A1 AZITHROMYCIN DOSAGE FORMS WITH REDUCED SIDE EFFECTS 审中-公开
标题翻译：阿奇霉素剂型减少副作用
公开(公告)号：WO2005053650A1
公开(公告)日：2005-06-16
申请号：PCT/IB2004/001654
申请日：2004-05-14
申请人： PFIZER PRODUCTS INC. , HAGEN, Timothy, Arthur , HERBIG, Scott, Max , LO, Julian, Belknap , THOMBRE, Avinash, Govind , APPEL, Leah, Elizabeth , CREW, Marshall, David , FRIESEN, Dwayne, Thomas , LYON, David, Keith , MCCRAY, Scott, Baldwin , WEST, James, Blair
发明人： HAGEN, Timothy, Arthur , HERBIG, Scott, Max , LO, Julian, Belknap , THOMBRE, Avinash, Govind , APPEL, Leah, Elizabeth , CREW, Marshall, David , FRIESEN, Dwayne, Thomas , LYON, David, Keith , MCCRAY, Scott, Baldwin , WEST, James, Blair
IPC分类号： A61K9/16
CPC分类号： A61K9/1611 , A61K9/143 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1694 , A61K9/2009 , A61K9/2013 , A61K9/2031 , A61K31/7052
摘要： An oral dosage form comprising azithromycin and an effective amount of an alkalizing agent. Preferably, said oral dosage form comprises an effective amount of an alkalizing agent and an azithromycin multiparticulate wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate, and a poloxamer. Typically, the oral dosage form includes any suitable oral dosing means such as a powder for oral suspension, a unit dose packet or sachet, a tablet or a capsule.Additionally disclosed is an oral suspension comprising azithromycin, an effective amount of an alkalizing agent and a vehicle. Preferably, the azithromycin is in multiparticulate form wherein said multiparticulate comprises azithromycin, a mixture of glyceryl monobehenate, glyceryl dibehenate and glyceryl tribehenate,and a poloxamer. Also disclosed is a method for reducing gastrointestinal side effects, associated with administering azithromycin to a mammal, comprising contiguously administering azithromycin and an effective amount of alkalizing agent to said mammal wherein the frequency of gastrointestinal side effects is lower than that experienced by administering an equal dose of azithromycin without said alkalizing agent.Further disclosed is a method of treating a bacterial or protozoal infection in a mammal in need thereof comprising contiguously administering to said mammal a single dose of an oral dosage form wherein said oral dosage form comprises azithromycin and an effective amount of an alkalizing agent.Additionally disclosed are azithromycin multiparticulates comprising azithromycin, a surfactant; and a pharmaceutically acceptable carrier.
摘要翻译：口服剂型包含阿奇霉素和有效量的碱化剂。优选地，所述口服剂型包含有效量的碱化剂和阿奇霉素多颗粒，其中所述多颗粒包含阿奇霉素，单山gly酸甘油酯，二山ate酸甘油酯和三山gly酸甘油酯的混合物以及泊洛沙姆。典型地，口服剂型包括任何合适的口服给药方式，例如用于口服悬浮液的粉剂，单位剂量小包或小药囊，片剂或胶囊。另外公开的是口服悬浮液，其包含阿奇霉素，有效量的碱化剂和一辆车。优选地，阿奇霉素为多颗粒形式，其中所述多颗粒包含阿奇霉素，单山gly酸甘油酯，二山ate酸甘油酯和三山gly酸甘油酯以及泊洛沙姆的混合物。还公开了用于减少与阿奇霉素给予哺乳动物有关的胃肠副作用的方法，包括向所述哺乳动物连续施用阿奇霉素和有效量的碱化剂，其中胃肠副作用的频率低于施用等剂量进一步公开了在有需要的哺乳动物中治疗细菌或原生动物感染的方法，其包括向所述哺乳动物连续施用单剂量的口服剂型，其中所述口服剂型包含阿奇霉素和有效量另外公开的是阿奇霉素多微粒，其包含阿奇霉素，表面活性剂; 和药学上可接受的载体。

6. 发明申请

WO2005053640A2 AZITHROMYCIN MULTIPARTICULATE DOSAGE FORMS BY LIQUID-BASED PROCESSES 审中-公开
标题翻译： AZITHROMYCIN基于液体过程的多重剂量形式
公开(公告)号：WO2005053640A2
公开(公告)日：2005-06-16
申请号：PCT/IB2004003911
申请日：2004-11-29
申请人： PFIZER PROD INC , APPEL LEAH ELIZABETH , CREW MARSHALL DAVID , FRIESEN DWAYNE THOMAS , LYON DAVID KEITH , MCCRAY SCOTT BALDWIN , RAY RODERICK JACK , WEST JAMES BLAIR
发明人： APPEL LEAH ELIZABETH , CREW MARSHALL DAVID , FRIESEN DWAYNE THOMAS , LYON DAVID KEITH , MCCRAY SCOTT BALDWIN , RAY RODERICK JACK , WEST JAMES BLAIR
IPC分类号： A61K9/00 , A61K9/14 , A61K9/16 , A61K9/52 , A61K31/7048 , B29B9/00
CPC分类号： A61K9/1652 , A61K9/1676 , A61K31/7048
摘要： Liquid-based processes are disclosed for forming azithromycin multiparticulates having minimal amounts of azithromycin esters.
摘要翻译：公开了用于形成具有最少量的阿奇霉素酯的阿奇霉素多颗粒的基于液体的方法。

7. 发明申请

WO2005020929A2 SUSTAINED RELEASE DOSAGE FORMS OF ZIPRASIDONE 审中-公开
标题翻译：持续释放ZIPRASIDONE的剂型
公开(公告)号：WO2005020929A2
公开(公告)日：2005-03-10
申请号：PCT/US2004/028304
申请日：2004-08-31
申请人： AHMED, Imran , APPEL, Leah, Elizabeth , BABCOCK, Walter, Christian , FRIESEN, Dwayne, Thomas , HERBIG, Scott, Max , LYON, David, Keith , SHAMBLIN, Sheri, L. , SHANKER, Ravi, Mysore , SMITHEY, Daniel, Tod , SUTTON, Steven, C. , THOMBRE, Avinash, Govind , WATERMAN, Kenneth, C.
发明人： AHMED, Imran , APPEL, Leah, Elizabeth , BABCOCK, Walter, Christian , FRIESEN, Dwayne, Thomas , HERBIG, Scott, Max , LYON, David, Keith , SHAMBLIN, Sheri, L. , SHANKER, Ravi, Mysore , SMITHEY, Daniel, Tod , SUTTON, Steven, C. , THOMBRE, Avinash, Govind , WATERMAN, Kenneth, C.
IPC分类号： A61K
CPC分类号： A61K9/1617 , A61K9/0004 , A61K9/1652 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/2081 , A61K9/209 , A61K9/2846 , A61K9/5047 , A61K31/496 , A61K31/4965
摘要： A sustained release solid oral dosage from for treatment of a psychotic disorder, for example schizophrenia, in a mammal is provided, which oral dosage from comprises ziprasidone in an amount effective in treating said psychotic disorder and a pharmaceutically acceptable carrier.
摘要翻译：提供了一种用于治疗哺乳动物精神病性精神分裂症的持续释放固体口服剂量，其口服剂量包含有效治疗所述精神病性障碍的量的齐拉西酮和药学上可接受的载体。

8. 发明申请

WO2004056359A1 DOSAGE FORMS COMPRISING A CETP INHIBITOR AND AN HMG-COA REDUCTASE INHIBITOR 审中-公开
标题翻译：包含CETP抑制剂和HMG-COA还原酶抑制剂的剂型
公开(公告)号：WO2004056359A1
公开(公告)日：2004-07-08
申请号：PCT/IB2003/006087
申请日：2003-12-12
申请人： PFIZER PRODUCTS INC. , FRIESEN, Dwayne, Thomas , LORENZ, Douglas, Alan , LYON, David, Keith , HANCOCK, Bruno, Caspar , MCDERMOTT, Timothy, Joseph , SHANKER, Ravi, Mysore
发明人： FRIESEN, Dwayne, Thomas , LORENZ, Douglas, Alan , LYON, David, Keith , HANCOCK, Bruno, Caspar , MCDERMOTT, Timothy, Joseph , SHANKER, Ravi, Mysore
IPC分类号： A61K31/40
CPC分类号： A61K45/06 , A61K9/146 , A61K9/1652 , A61K9/2054 , A61K9/2077 , A61K9/2081 , A61K9/209 , A61K31/00 , A61K31/40 , A61K31/4706 , A61K2300/00
摘要： A dosage form comprises (1) a solid amorphous dispersion comprising a cholesteryl ester transfer protein inhibitor and an acidic concentrationenhancing polymer and (2), an HMG-CoA reductase inhibitor. The solid amorphous dispersion and the HMG-CoA reductase inhibitor are combined in the dosage form so that the solid amorphous dispersion and the HMG-CoA reductase inhibitor are substantially separate from one another in the dosage form.
摘要翻译：剂型包括（1）包含胆固醇酯转移蛋白抑制剂和酸性浓缩增强聚合物的固体无定形分散体和（2）HMG-CoA还原酶抑制剂。将固体无定形分散体和HMG-CoA还原酶抑制剂以剂型组合，使得固体无定形分散体和HMG-CoA还原酶抑制剂在剂型中基本上彼此分离。

9. 发明申请

WO1994030020A1 DIGITAL SUBCARRIER REGENERATION APPARATUS FOR USE IN VIDEO SIGNAL PROCESSING 审中-公开
标题翻译：用于视频信号处理的数字辅助再生设备
公开(公告)号：WO1994030020A1
公开(公告)日：1994-12-22
申请号：PCT/GB1994001253
申请日：1994-06-10
申请人： SNELL & WILCOX LIMITED , LYON, David , SOMERVILLE, Stuart
发明人： SNELL & WILCOX LIMITED
IPC分类号： H04N09/455
CPC分类号： H04N9/455 , H04N9/8707
摘要： Subcarrier is regenerated digitally from a video signal which has a line frequency that cannot be assumed to be constant. Subcarrier samples at the line-locked frequency are compared, using digital or analogue means, with a reference subcarrier derived from a crystal locked oscillator. The frequency of the subcarrier samples is controlled in feedback to produce subcarrier of accurate frequency in the line-locked digital environment.
摘要翻译：子载波从具有不能被假定为恒定的线路频率的视频信号数字地再生。使用数字或模拟装置将来自锁定频率的子载波样本与从晶体锁定振荡器导出的参考子载波进行比较。子载波样本的频率在反馈中被控制，以在线锁数字环境中产生准确频率的副载波。

10. 发明申请

WO1994001970A1 MOTION COMPENSATED VIDEO PROCESSING 审中-公开
标题翻译：运动补偿视频处理
公开(公告)号：WO1994001970A1
公开(公告)日：1994-01-20
申请号：PCT/GB1993001404
申请日：1993-07-05
申请人： SNELL & WILCOX , MARTIN, Philip, David , BORER, Timothy, John , LYON, David
发明人： SNELL & WILCOX
IPC分类号： H04N07/01
CPC分类号： H04N19/513 , H04N7/014 , H04N19/521
摘要： Method of motion-compensated video processing such as standards conversion, uses motion vectors assigned on a pixel-by-pixel basis. The pixels of an input video signal are written to locations in a video store (24) determined by the motion vector assigned to that pixel. Multiple vectors can address a single written pixel to enable mixing of backward and forward vectors. A confidence value governs the accumulation of pixels and the later interpolation between motion compensated fields.
摘要翻译：诸如标准转换的运动补偿视频处理的方法使用以逐个像素为基础分配的运动矢量。将输入视频信号的像素写入由分配给该像素的运动矢量确定的视频存储器（24）中的位置。多个向量可以寻址单个写入像素以使后向和向前向量的混合。置信度值控制像素的累积和运动补偿场之间的后期插值。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式